Condition: Plasma Cell Myeloma Refractory · Sponsor: Sanofi
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free number for US & Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Winship Cancer Institute of Emory University- Site Number : 8400010 | Atlanta, Georgia, United States | Recruiting |
| University of Illinois-Chicago - College of Medicine- Site Number : 8400007 | Chicago, Illinois, United States | Completed |
| University of Michigan Health System - Ann Arbor- Site Number : 8400004 | Ann Arbor, Michigan, United States | Recruiting |
| Roswell Park Cancer Institute- Site Number : 8400008 | Buffalo, New York, United States | Recruiting |
| The Ohio State University- Site Number : 8400012 | Columbus, Ohio, United States | Recruiting |
| Investigational Site Number : 0360006 | Wollongong, New South Wales, Australia | Recruiting |
| Investigational Site Number : 0360002 | Melbourne, Victoria, Australia | Recruiting |
| Investigational Site Number : 0360001 | Richmond, Victoria, Australia | Recruiting |
| Investigational Site Number : 2500003 | Paris, Washington, France | Recruiting |
| Investigational Site Number : 2500002 | Lille, France | Recruiting |
| Investigational Site Number : 2500001 | Nantes, France | Recruiting |
| Investigational Site Number : 2500004 | Paris, France | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04643002